Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
- Author:
Yalin XIE
1
;
JiZhen LIANG
;
Ning SU
Author Information
- Publication Type:Journal Article
- MeSH: Carcinoma, Non-Small-Cell Lung; drug therapy; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Lung Neoplasms; drug therapy; Mutation; Quinazolines; therapeutic use; Receptor, Epidermal Growth Factor; metabolism
- From: Journal of Southern Medical University 2015;35(3):446-449
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.
METHODSFifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib.
RESULTSThere were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293).
CONCLUSIONThere is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.
